<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39370709</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2001-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Clinical and translational medicine</Title><ISOAbbreviation>Clin Transl Med</ISOAbbreviation></Journal><ArticleTitle>Prediction of COVID-19 severity using machine learning.</ArticleTitle><Pagination><StartPage>e70042</StartPage><MedlinePgn>e70042</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70042</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/ctm2.70042</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karaduzovic-Hadziabdic</LastName><ForeName>Kanita</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Faculty of Engineering and Natural Sciences, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adilovic</LastName><ForeName>Muhamed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Engineering and Natural Sciences, International University of Sarajevo, Sarajevo, Bosnia and Herzegovina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Bioinformatics Platform, Luxembourg Institute of Health, Strassen, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumley</LastName><ForeName>Andrew I</ForeName><Initials>AI</Initials><AffiliationInfo><Affiliation>Cardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Pranay</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoaib</LastName><ForeName>Muhammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Luxembourg Center for Systems Biomedicine, University of Luxembourg, Belval, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satagopam</LastName><ForeName>Venkata</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Luxembourg Center for Systems Biomedicine, University of Luxembourg, Belval, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Prashant Kumar</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emanueli</LastName><ForeName>Costanza</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greco</LastName><ForeName>Simona</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madè</LastName><ForeName>Alisia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padro</LastName><ForeName>Teresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Cardiovascular Program-ICCC, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU); CIBERCV; Autonomous University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domingo</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiovascular Program-ICCC, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU); CIBERCV; Autonomous University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lustrek</LastName><ForeName>Mitja</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Intelligent Systems, Jozef Stefan Institute, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Group Genetical Statistics and Biomathematical Modelling, Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosolowski</LastName><ForeName>Maciej</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Group Genetical Statistics and Biomathematical Modelling, Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jordan</LastName><ForeName>Marko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Intelligent Systems, Jozef Stefan Institute, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benczik</LastName><ForeName>Bettina</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cardiometabolic and HUN-REN-SU System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Pharmacology and Drug Research &amp; Development, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmahungary Group, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ágg</LastName><ForeName>Bence</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cardiometabolic and HUN-REN-SU System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Pharmacology and Drug Research &amp; Development, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmahungary Group, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferdinandy</LastName><ForeName>Péter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiometabolic and HUN-REN-SU System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Pharmacology and Drug Research &amp; Development, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmahungary Group, Szeged, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Andrew H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, Scotland, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, CARIM, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagherazzi</LastName><ForeName>Guy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Deep Digital Phenotyping Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ollert</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infection and Immunity, Luxembourg Institute of Health, Esch-Sur-Alzette, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michel</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Firalis SA, Huningue, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Firalis SA, Huningue, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Firat</LastName><ForeName>Hüseyin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Firalis SA, Huningue, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brandenburger</LastName><ForeName>Timo</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University Hospital Düsseldorf, Heinrich-Heine University Duesseldorf, Moorenstr, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martelli</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-8624-7738</Identifier><AffiliationInfo><Affiliation>Molecular Cardiology Laboratory, IRCCS Policlinico San Donato, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badimon</LastName><ForeName>Lina</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-9162-2459</Identifier><AffiliationInfo><Affiliation>Cardiovascular Program-ICCC, Institut d'Investigació Biomèdica Sant Pau (IIB SANT PAU); CIBERCV; Autonomous University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Devaux</LastName><ForeName>Yvan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5321-8543</Identifier><AffiliationInfo><Affiliation>Cardiovascular Research Unit, Department of Precision Health, Luxembourg Institute of Health, Strassen, Luxembourg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVIRNA consortium (www.covirna.eu)</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>101016072</GrantID><Agency>Horizon 2020 Framework Programme</Agency><Country /></Grant><Grant><Agency>André Losch Fondation</Agency><Country /></Grant><Grant><Agency>Heart Foundation-Daniel Wagner of Luxembourg,</Agency><Country /></Grant><Grant><GrantID>POS T4 CAL.HUB.RIA cod. T4-AN-09</GrantID><Agency>Ministero della Salute</Agency><Country /></Grant><Grant><GrantID>RF-2019-12368521</GrantID><Agency>Ministero della Salute</Agency><Country /></Grant><Grant><GrantID>Ricerca Corrente 2024 1.07.128</GrantID><Agency>Ministero della Salute</Agency><Country /></Grant><Grant><GrantID>C14/BM/8225223</GrantID><Agency>Fonds National de la Recherche Luxembourg</Agency><Country /></Grant><Grant><GrantID>C17/BM/11613033</GrantID><Agency>Fonds National de la Recherche Luxembourg</Agency><Country /></Grant><Grant><GrantID>COVID-19/2020-1/14719577/miRCOVID</GrantID><Agency>Fonds National de la Recherche Luxembourg</Agency><Country /></Grant><Grant><GrantID>Predi-COVID/14716273</GrantID><Agency>Fonds National de la Recherche Luxembourg</Agency><Country /></Grant><Grant><Agency>Next Generation EU, PNRR M6C2 Inv. 2.1 PNRR-MAD-2022-12375790 and PNRR/2022/C9/MCID/I8 FibroThera</Agency><Country /></Grant><Grant><GrantID>2018-04-026-21</GrantID><Agency>European Regional Development Fund, FEDER, convention</Agency><Country /></Grant><Grant><Agency>Ministry of Higher Education and Research, Luxembourg</Agency><Country /></Grant><Grant><GrantID>RRF-2.3.1-21-2022-00003</GrantID><Agency>European Union</Agency><Country /></Grant><Grant><GrantID>2020-1.1.5-GYORSÍTÓSÁV</GrantID><Agency>Ministry for Innovation and Technology / National Research Development and Innovation Fund</Agency><Country /></Grant><Grant><GrantID>2020-1.1.6-JÖVŐ-2021-00013</GrantID><Agency>"Befektetés a jövőbe" NKFIH</Agency><Country /></Grant><Grant><Agency>HUN-REN Hungarian Research Network</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Transl Med</MedlineTA><NlmUniqueID>101597971</NlmUniqueID><ISSNLinking>2001-1326</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>YD holds patents and licensing agreements related to the use of RNAs for diagnostic and therapeutic purposes (WO2018229046, licensed to Firalis SA, protecting the use of lncRNAs in the FIMICS panel used for RNAseq in the present paper; other patents and licenses are not related to the present work). YD is Scientific Advisory Board member of Firalis SA. PF is the founder and CEO of Pharmahungary Group, a group of R&amp;D companies. LB declares to have acted as a SAB member of Sanofi, Ionnis, MSD and NovoNordisk; to have received speaker fees from Sanofi, Bayer and AB‐Biotics SA and to have founded the spin‐off Ivastatin Therapeutics S.L. (all unrelated to this work). TP declares to have received speaker fees from AB‐Biotics SA and to be a co‐founder of the Spin‐off Ivastatin Therapeutics SL (all unrelated to this work). MS received funding from Pfizer Inc. and from Owkin for projects not related to this research. HF is the founder and owner of Firalis SA, a company commercialising the FIMICS panel. He holds patents and licenses for the use of RNAs as biomarkers and therapeutic targets. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>2</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39370709</ArticleId><ArticleId IdType="pmc">PMC11456675</ArticleId><ArticleId IdType="doi">10.1002/ctm2.70042</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
World Health Organization
. WHO COVID‐19 Dashboard. data.who.int. http://data.who.int/dashboards/covid19/cases
</Citation></Reference><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, et al. Development of a definition of postacute sequelae of SARS‐CoV‐2 infection. JAMA. 2023;329:1934‐1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Caporali A, Anwar M, Devaux Y, et al. Non‐coding RNAs as therapeutic targets and biomarkers in ischaemic heart disease. Nat Rev Cardiol 2024:1‐18, doi:10.1038/s41569-024-01001-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-024-01001-5</ArticleId><ArticleId IdType="pubmed">38499868</ArticleId></ArticleIdList></Reference><Reference><Citation>Badimon L, Devaux Y. Transcriptomics research to improve cardiovascular healthcare. Eur Heart J. 2020;41:3296‐3298.</Citation><ArticleIdList><ArticleId IdType="pubmed">33033839</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes CPC, Ágg B, Andova A, et al. Catalyzing transcriptomics research in cardiovascular disease: the CardioRNA COST Action CA17129. Noncoding RNA. 2019;5:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6630366</ArticleId><ArticleId IdType="pubmed">30934986</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson EL, Emanueli C, Martelli F, et al. Leveraging non‐coding RNAs to fight cardiovascular disease: the EU‐CardioRNA network. Eur Heart J. 2021;42:4881‐4883.</Citation><ArticleIdList><ArticleId IdType="pubmed">34109376</ArticleId></ArticleIdList></Reference><Reference><Citation>Badimon L, Robinson EL, Jusic A, et al. Cardiovascular RNA markers and artificial intelligence may improve COVID‐19 outcome: a position paper from the EU‐CardioRNA COST Action CA17129. Cardiovasc Res. 2021;117, 1823‐1840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083253</ArticleId><ArticleId IdType="pubmed">33839767</ArticleId></ArticleIdList></Reference><Reference><Citation>Firat H., Zhang L, Baksi S, et al. FIMICS: a panel of long noncoding RNAs for cardiovascular conditions. Heliyon. 2023;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9898641</ArticleId><ArticleId IdType="pubmed">36747920</ArticleId></ArticleIdList></Reference><Reference><Citation>Karađuzović‐Hadžiabdić K, Peters A. Chapter 15 – artificial intelligence in clinical decision‐making for diagnosis of cardiovascular disease using epigenetics mechanisms. In Devaux Y, Robinson EL, eds., Epigenetics in Cardiovascular Disease, Vol. 24. Academic Press; 2021:327‐345.</Citation></Reference><Reference><Citation>Devaux Y, Zhang L, Lumley AI, et al. Development of a long noncoding RNA‐based machine learning model to predict COVID‐19 in‐hospital mortality. Nat Commun. 2024;15:4259</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11106268</ArticleId><ArticleId IdType="pubmed">38769334</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>